NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.

NCT05576051

CompletedN/A

Sponsor: Pfizer

Conditions: Rheumatoid Arthritis

Interventions: patterns of use of combination therapy and monotherapy

Countries: United States

To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* RA patients in Corrona initiating a TNFi biologic (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) during follow-up in Corrona with no prior use of Tofacitinib

Exclusion Criteria:

* Patients with no history of cDMARD but history of 1+ biologics - these cases will be excluded from analyses
* Patients using combination therapy with a cDMARD other than MTX will be excluded
* Patients using combination therapy of MTX and another cDMARD will be excluded

Locations (1)

New York, New York, United States